In a transformative move for the neurotechnology sector, Vivani Medical has announced a definitive agreement to merge its subsidiary, Cortigent, with ClearOne, a specialist in communications equipment. This strategic transaction is set to reshape the landscape of brain-computer interface (BCI) development by providing Cortigent with a direct path to a Nasdaq listing, effectively spinning it out as a standalone public entity under the name "Cortigent Holdings."
The deal, which is anticipated to close in the third quarter of 2026, marks a pivotal moment for both companies. For Vivani, the merger allows for a cleaner operational focus on its core pharmaceutical implant business, while for Cortigent, it provides the capital and public market visibility necessary to accelerate its high-stakes clinical pipeline.
The Mechanics of the Merger
Under the terms of the agreement, the transaction will involve a complex equity restructuring designed to align the interests of existing shareholders while securing the future of the new entity. Vivani Medical will receive 12.5 million shares of ClearOne common stock. Post-closing, Vivani is expected to hold between 59.4% and 67.5% of the outstanding equity in the combined company. Conversely, legacy shareholders of ClearOne will retain a stake ranging from 12.7% to 14.4%.
The new entity, Cortigent Holdings, will trade on the Nasdaq under the ticker symbol "CRGT." To bolster the transition and ensure the development of its BCI product pipeline remains on track, the company plans to raise between $10 million and $15 million through a concurrent share offering.
ClearOne’s existing business—professional audio, video, and collaboration systems utilized in high-end boardrooms and educational facilities—will transition into a "non-core legacy" segment within the new corporate structure.
Chronology of Evolution: From Second Sight to Cortigent
The path to this merger is deeply rooted in the history of medical innovation. Cortigent’s current portfolio is not a recent invention but the result of years of consolidation within the neurotech space.
- 2022: A landmark merger occurred between Second Sight Medical, a pioneer in retinal prosthetics, and Nano Precision Medical. This union formed the entity now known as Vivani Medical.
- The Inheritance: Through this integration, Vivani acquired the intellectual property and development programs originally pioneered by Second Sight, including the Argus II retinal prosthesis.
- Present Day: Recognizing the need for specialized management and capital allocation, Vivani moved to isolate its BCI and neurostimulation assets into the subsidiary Cortigent.
- 2026 Q3 (Projected): The finalization of the merger with ClearOne, marking the birth of Cortigent Holdings as a publicly traded company.
The Technological Pipeline: Restoring Sight and Mobility
The value proposition for Cortigent Holdings rests on a suite of advanced neurostimulation technologies. The most prominent of these include:
1. The Orion BCI
Orion represents a significant leap in artificial vision technology. Unlike older systems, this BCI implant is designed to bypass damaged eyes and transmit visual information directly to the brain’s visual cortex. It is intended to offer meaningful visual perception to individuals who have lost their sight, moving beyond mere light-detection to a more functional, usable sense of environment.
2. The Argus II Retinal Prosthesis
The Argus II, a surgically implanted device, is designed to restore a form of "artificial vision" to individuals suffering from severe retinitis pigmentosa. By stimulating the remaining retinal cells, the system provides patients with the ability to navigate their surroundings and identify objects, a life-altering advancement for those with degenerative retinal conditions.
3. Stroke Recovery Innovations
Beyond vision, Cortigent is expanding its reach into motor function restoration. The company is currently developing a new device—leveraging the same foundational BCI technology found in its vision products—to assist in the recovery of hand and arm mobility. By targeting the neural pathways affected by partial paralysis post-stroke, Cortigent aims to shorten rehabilitation timelines and improve long-term patient outcomes.
Official Responses and Strategic Rationale
The executive leadership on both sides of the deal has expressed optimism regarding the synergy of the merger.
Adam Mendelsohn, CEO of Vivani Medical, emphasized that the primary driver for this deal is efficiency. "This agreement serves to reduce our direct expenditures relating to Cortigent," Mendelsohn stated. By offloading the capital-intensive nature of neurotech development into a dedicated holding company, Vivani can concentrate its resources on its proprietary long-acting drug implant portfolio, a business line that requires a distinct operational focus.
Eric Robinson, Board Chair of ClearOne, highlighted the social and technical significance of the merger. "Cortigent’s mission to help patients recover sight and motor function through precision neurostimulation is compelling," Robinson noted. He pointed to both the technical robustness of the neurostimulation platform and the immense, unmet clinical needs as the primary justifications for the merger. "We anticipate that the planned financing will give the combined company a strong foundation to move its pipeline forward," he added.
Market Implications and Data Analysis
The market reaction to the announcement was swift and dramatic. Following the news, ClearOne’s shares surged over 100% on the Nasdaq, closing at $6.48 on July 2, 2026, up from an opening price of $3.60. With a market capitalization hovering around $17.34 million, the company is now positioned to leverage its new identity to attract growth-oriented investors interested in the high-barrier-to-entry neurotech space.
The Broader Neurology Landscape
The timing of this merger aligns with a massive shift in healthcare investment. GlobalData analysis forecasts that the neurology devices market is on a trajectory to exceed $25 billion by 2034. BCI technology, in particular, is moving from the realm of academic research into commercial reality.
Morgan Stanley analysts have estimated that the Total Addressable Market (TAM) for BCI technology among US adults could reach $80 billion, impacting approximately three million people. With further advancements in biocompatibility, surgical precision, and data processing, this market potential could potentially quadruple to $320 billion.
The Future of Cortigent Holdings
As Cortigent Holdings prepares to take its place on the Nasdaq, it faces both significant opportunities and typical "startup" challenges. The company must prove that its clinical pipeline can clear regulatory hurdles and transition into widespread adoption.
The strategy of merging with an established, albeit legacy, public company (a "reverse-like" structure) is a well-tested mechanism for companies looking to bypass the lengthy and costly traditional IPO process. By inheriting the listing status of ClearOne, Cortigent Holdings gains immediate access to the public markets, which is critical for a firm operating in the capital-intensive world of implantable medical devices.
The upcoming months will be a period of structural adjustment. As ClearOne’s communication business is moved to the background, investors will be watching to see how the management team prioritizes the Orion and stroke-recovery programs. For the patients suffering from blindness and paralysis, the success of this entity represents more than just a stock ticker; it represents the potential for a return to functional independence.
In conclusion, the merger between Vivani’s Cortigent subsidiary and ClearOne is a calculated strategic maneuver that reflects the growing maturity of the neurotech industry. By aligning public capital with groundbreaking BCI innovation, the newly formed Cortigent Holdings is positioning itself at the forefront of a medical revolution that promises to redefine the boundaries of human recovery.
About the Author
